Plasmin-mediated proteolysis of tissue factor pathway inhibitor: Potential contributing mechanism to rethrombosis despite heparin administration following fibrinolytic therapy  by Becker, Richard C. et al.
JACC March 19,2003 
vasodilator (Bk, 50 pl , 1OS8,5 to 1 O6 M) were recorded before and after global zero-flow 
normotherme I/R ( 40140 min. ) on 14 isolated perfused rat hearts. Coronary bloodflow 
(CBF) changes were expressed as the percentage of baseline flow. Folate (4,5 .lO%l )
was added on the affluent of 7 hearts during 30 min as a pretreatment before IR. 7 con- 
trol hearts received only Krebs-solution as pre-treatment. IR caused a significant reduc- 
tion ot the vasodilator responses to Bk (pcO.01). However, after pretreatment with folate, 
the vasodilator respons to Bk remained unchanged after IR (p>O.O5). 
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1024-106 A Functional Erythropoietin Receptor in a Rat Heart Is 
Linked to Anti-Apoptotic Effects 
Peter van der Meer, Erik Lipsic, Rudolf A. de Boer, Rob H. Henning, Dirk J. van 
Veldhuisen, Wiek H. van Gilst, University of Groningen. Groningen, The Netherlands, 
University Hospital Groningen, Groningen, The Netherlands 
Background Recent experiments show that erythropoietin (EPO) plays a protective role 
in brain ischemia. In this condition, the EPO receptor (EPO-R) are upregulated and 
administration of EPO provides protection against apoptosis. It is unknown whether the 
EPO-R is expressed in the heart and if EPO exerts similar beneficial effects during 
hypoxic stress in cardiac cells. We report the first evidence that a functional EPO-R is 
expressed in rat cardiac tissue and EPO plays an anti-apoptotlc role. Methods First we 
studied the functionality of the EPO-R. by incubating rat cardiac tissue (n=4) for one hour 
with increasing doses EPO (control, 1CJ’ U/ml, 10-l U/ml, and 1 U/ml) and measuring 
STAT-5 phosphorylation by Western Blotting. To further evaluate the effects of EPO, we 
induced low-flow ischemia (30 min at 1.7 mllmin) followed by 45 min of reperfusion in 
Langendorff perfused rat hearts. Four groups of hearts were used: control hearts (n =6), 
control healts that were perfused with EPO (0.3U/ml) (n =6), hearts subjected to low flow 
ischemia with EPO (n=6) and without EPO administration (n=6). After the experiments, 
cardiac tissue was harvested for RT-PCR. immunohistochemistry and apoptosis detec- 
tion, assessed by determining the Bcl-2lBax ratio. Results Incubation of rat cardiac tis- 
sue with 113’ U/ml, lo” U/ml and 1 U/ml EPO showed a 2.4.. 3.7-, and 4.1.fold increase 
in phospholylated STAT-5 expression, respectively. Furthermore, EPO-R mRNA was 
detected in both normal and ischemic hearts, assessed by RT-PCR. With immunohis- 
tochemistry we found that cardiomyocytes. smooth muscle cells and endothelial cells 
expressed the EPO-R. Administration of EPO during ischemia and reperfusion exerted 
an increase in the Bcl-2/Bax ratio, compared with the non-treated group. Conclusion A 
functional EPO-R is present in rat heart as evidenced by STAT-5 phosphorylation and 
tissue expression. Furthermore, administration of EPO may protect cardiac cells from 
apoptosis following ischemia and reperiusion. 
1024-l 07 Early Activation of Matrix Metalloproteinase After 
Myocardial Infarction in Rats 
Jason Wollmuth, Nicholle Johnson, Steven Goldman, Mohamed A. Gaballa, University of 
Arizona Sarver Heart Center, Tucson, AZ, Southern Arizona VA Health Care System, 
Tucson, AZ 
We examined MMP activation early after Ml in rats. MMP zymographic activity was mea- 
sured in LV myocardial extracts. Immediately after MI, there is an increased (PcO.05) in 
LV end-diastolic pressure (LVEDP), decrease (PcO.05) in both LV dP/dt and LV systolic 
pressure. Maximum increase in LVEDP and decrease in LVdPIdt, and LV systolic pres- 
sure occured at 5-minute after MI,. Myocardial MMP-2 was detected in normal control tis- 
sue (17.8426.7 lllpg protein), and at each time point examined between immediately and 
21 days after Ml. The increase in MMP-2 activity reached significance at 4 min after Ml 
(34.98k7.64 vs. 22.96 * 4.22 II/w protein, PcO.05). MMP-2 activity decreased at times 
>5 minutes after Ml (24.4k4.3 vs 34.98i7.6 II/&g protein, PcO.05) and increased at 24 
and 48 hrs after MI (49.7;tl2.9, 55.6+13.7, respectively vs.17.84i6.7, ll/pg protein, 
PcO.05). There was another rise in MMP-2 activities at 7 days (65.8il2.7 vs. 17.8k6.7, 
II/)19 protein, PcO.05). Finally, MMP-2 activity was decreased at 21 days after Ml 
(85.8212.7 vs. 55.6~13.7 II/Kg protein, PcO.05) compared to MMP-2 activity at 7days 
after MI. MMP-9 activity was not observed in normal hearts or early after MI (~60 min- 
utes). However, MMP-9 activity increased at 3 hours (16.98 * 4.69 ll/pg protein, PcO.O5), 
at 24 (38.52 * 11.0 ll/pg protein, PcO.O5), and at 48 hours (53.84 * 20.59 II/Kg protein, 
P<O.O5. MMP-9 activity was absent at 7 and 21 days post Ml. MMP-13 activity was not 
observed in normal hearts but showed a increase immediately after Ml (34.15 * 14.61 Ill 
pg protein, P<O.O5). At 2 minutes (41.79 f 16.25 II& protein, P<O.O5). at 4 minutes 
(60.46 * 20.12 ll/pg protein), and at 5 minutes (113.43 * 45.54 II&g protein, PcO.05) 
after Ml. This activity, however, was not seen again at any time points after 5 minutes, 
except at 24 hr after Ml (89.42349 ll/pg protein). Active MMP-3 was seen in normal heart 
(control, 32.5e6.4) and at each time point measured except at 7 days after MI, where it 
decreased (12.5+3.7 vs 32.5~6.4 IlCg protein, PcO.05). However, proMMP-3 was only 
seen at 7 days after Ml. In conclusion, LV myocardlal MMP activity increases within min- 
utes of Ml and early changes in hemodynamic may be the precipitating factor. 
1024-l 08 Pretreatment With Folic Acid Prevents lschemial 
Reperfusion Induced Endothelial Dysfunction 
An L. Moens, Marc Claeys, Johan M. Bosmans, Jean-Pierre Timmermans. Christiaan J. 
Vrints, University of Antwerp Antwerp, Belgium 
Background: Endothelial dysfunction is one of the components of ischemialreperfu- 
sion(lR) injury. This study was designed to determine whether pre-treatment with folate 
can prevent endothelium-dependent coronary vasomotion after IR. Folate regenerates 
tetrahydrobiopterin, an essential cofactor of NO-synthase, lowers the homocysteine level 
and improves the antioxidant defence system. In patients with cardiovascular risks or 
with chronic coronary artery disease, folate improves endothelial function. 
Methods and Results: Vasodilator responses to bradykinin , an endothelium dependent 
Conclusion: Pretreatment with folic acid can prevent IR-induced endothelial dysfunc- 
tion. This pre-treatment mechanism represents possibly the basis for a new strategy in 
the therapy of patients with acute coronary syndromes. 
1024-l 09 Plasmin-Mediated Proteolysis of Tissue Factor Pathway 
Inhibitor: Potential Contributing Mechanism to 
Rethrombosls Despite Heparin Administration 
Following Fibrinolytic Therapy 
Richard C. Becker, YouFu Li, Frederick A. Spencer, Unrversity of Massachusetts Medical 
School, Worcester, MA 
Background: Coronary arterial reocclusion following successful fibrinolysis occurs in 10 
to 15% of patients despite heparin-based anticoagulant therapy. We have shown previ- 
ously that unfractionated heparin (UFH) depletes endothelial cell tissue factor pathway 
inhibitor (TFPI), an important component of vascular thromboresistance. Because plas- 
min. the active enzyme generated from plasminogen by fibrinolytics is a non-specific pro- 
tease, we determined its effect on endothelial cell TFPI. 
MethodslRasults: Human vascular endothelial cells (third passage) were grown to con- 
fluence on 24-well polysterene culture dishes precoated with gelatin at a density of 1.0 
Xl O5 cells per dish. The cells were incubated for two hours with varying concentrations of 
plasminogen, tPA and plasmin. TFPI (antigen) was measured by ELISA. All experiments 
were performed in triplicate. The results are summarized in the figure shown below. 
Conclusions: Plasmin, a non-specific protease generated in high concentrations follow- 
ing frbrinolytic therapy, decreases endothelial cell surface TFPI. The combined effects of 
UFH and plasmin may substantially impair antiprotease activity and vascular thrombore- 
sistance, contributing to coronary arterial rethrombosis. 
1024-110 Aldosterone Antagonism Improves Endothelial 
Dependent Vasorelaxatlon in Heart Failure via a Nitric 
Oxide Mediated Mechanism 
TrunkTran -1 Kent G. Meredith, Jason Wollmuth. Steven Goldman, Hoang Thai, Mohamed 
A. Gaballa, University of Arizona Salver Heart Center, Tucson, AZ, Southern Arizona VA 
Health Care System, Tucson, AZ 
Impaired nitric oxide (NO) mediated endothelial dependent vasorelaxation is significant 
in heart failure (HF). Clinical data demonstrate that therapies which improve NO medi- 
ated vasorelaxation by modulating the renin-angiotensin-aldosterone system also 
decrease mortality in subjects with HF. In the Randomized Aldactone Evaluation Study, 
the aldosterone antagonist, sprronolactone. reduced mortality of HF patients. Our study 
was designed to determine if spironolactone improves NO mediated endothelial depen- 
dent vasorelaxation. Myocardial infarcted (Ml) adult (8.10 weeks old) Sprague Dawley 
rats (n=lO) in HF were treated with spironolactone (7 mgikglday) for 4 weeks. At the end 
of the treatment period, all animals underwent hemodynamic studies. The heart and tho- 
